Rich Rieger

Rich Rieger is a managing director at BRG. He is a global healthcare leader with nearly thirty years of experience as a senior operating executive and advisor to biopharmaceutical and medtech companies and private equity (PE) firms and law firms.

Mr. Rieger specializes in biopharmaceutical and medtech company growth and performance improvement across corporate strategy, research and development (R&D) portfolio, partnering/mergers and acquisitions (M&A), commercialization (sales, marketing, pricing, market access), manufacturing, and operations excellence. The product scope for these initiatives includes primary care, specialty, and generics targeting community-based healthcare providers, hospitals and health systems, IDNs, GPOs, specialty pharmacies and distributors, commercial and Medicare/Medicaid payors, CMOs, CROs, FDA, EMA, and other global regulators, and other stakeholders in the value chain. His work encompasses restructuring and bankruptcy.

Mr. Rieger also specializes in expert support and testimony for issues in economics, disputes, and investigations during litigation and arbitration. Issues include R&D across preclinical and clinical development, regulatory, intellectual property, partnering/M&A, product launch and lifecycle management, sales and marketing, pricing and market access, reimbursement, manufacturing and supply chain, restructuring, bankruptcy, fair market valuation, and economic damages, among others. His work spans both federal and state matters.

Mr. Rieger advises PE firms on their investment theses, commercial and operational due diligence, transaction support, portfolio company improvement, interim management, and asset monetization.

Prior to BRG, Mr. Rieger was a managing director at Alvarez & Marsal and a principal at LEK Consulting. He was the GM/Head of Baxter’s Global Pharmaceuticals and Medical Products business, VP of Business Development at Horizon Therapeutics, and a director of Business Development and Marketing at AbbVie.

At Baxter, he accelerated the growth of its Global Pharmaceuticals and Medical Products business that now generates more than $2.5 billion in annual net sales. It includes products in the US, Canada, Europe, Asia, and Latin America. He transformed the business via core product expansion, R&D portfolio and marketed product investments utilizing acquisitions and strategic alliances, and operational improvements.

At Horizon Therapeutics, he created a global rare disease strategy that resulted in the TEPEZZA acquisition and the company’s transformation. He also advised a PE firm on its acquisition and commercial strategy for KRYSTEXXA, which was later acquired by Horizon. Together, these products generated $2.7 billion in 2022 annual net sales that led to significant value creation and Amgen’s acquisition of Horizon for $28 billion.

At AbbVie, he led strategy, portfolio management, partnering/M&A, alliance management, and marketing initiatives. It included the acquisition and commercialization of primary care and specialty pharmaceuticals like SYNAGIS, HUMIRA, LUPRON, FLOMAX, MOBIC, MICARDIS, and emtricitabine that later became part of Gilead’s HIV combination products.

As an advisor, he supported Bristol Myers-Squibb on a key strategy that led to many transformative deals, including the development and commercialization of breakthrough immuno-oncology products like OPDIVO and YERVOY that are global leaders.

As an expert advisor on biopharmaceuticals and damages, he supported investors on a pharmaceutical company bankruptcy and restructuring, including the assessment of its product portfolio and business plan, providing insights regarding its pricing strategy, and commercial and Medicare claim estimates to inform potential damages owed by the company.

As a PE advisor, he has supported PE firms on global M&A investments and performance optimization initiatives in biopharmaceuticals, medtech, and related services like CMOs, CDMOs, and CROs.

Mr. Rieger also applies his business and scientific experience at nonprofit organizations.

At the Gateway for Cancer Research, he serves on the Scientific Advisory Board. He has evaluated ~400 investigator-initiated oncology clinical trials, advised on their designs, and provided funding to accelerate practice-changing cancer care.

At the National Marrow Donor Program (NMDP), he served on the Board of Directors. NMDP is a leader in cell therapy that facilitates stem cell transplants for patients with blood cancers and disorders, impacting more than 7,000 patients annually.

Mr. Rieger earned an MBA at the University of Chicago in finance and general management and a BS in electrical engineering at the University of Notre Dame.